查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835595

多发性骨髓瘤药物市场按药物类别、治疗线、治疗方法、给药途径、患者年龄、性别和分销渠道划分 - 全球预测 2025-2032

Multiple Myeloma Drug Market by Drug Class, Line Of Therapy, Treatment Regimen, Route Of Administration, Patient Age, Gender, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，多发性骨髓瘤治疗市场将成长至 463.2 亿美元，复合年增长率为 8.27%。

主要市场统计数据
基准年2024年 245.1亿美元
预计2025年 265.2亿美元
预测年份：2032年 463.2亿美元
复合年增长率（%） 8.27%

一份全面的概述文件，定义了治疗层级、临床决策节点和治疗实施变量，这些变量影响了多发性骨髓瘤的管理

多发性骨髓瘤已从骨髓恶性肿瘤演变为一个复杂且需要长期管理的疾病领域，其特点是快速的治疗创新和细緻入微的患者治疗路径。目前，该领域涵盖了标靶小分子药物、免疫调节化合物、生技药品和精准定向平台，每种药物都在改变临床实践模式和付款人互动。在此背景下，相关人员需要一份简明的、基于证据的介绍，阐明治疗类别、其实际给药路径以及影响其应用的商业性槓桿。

本执行导言透过阐明目前的治疗分类和常见的临床决策标准奠定了基础。关键药物类别包括组蛋白去乙酰化酶抑制剂，例如Panobinostat；免疫调节剂，例如Lenalidomide胺、泊马度Pomalidomide和Thalidomide；单株抗体，例如Daratumumab尤单抗、Elotuzumab和伊沙妥昔单抗；以及蛋白酶体抑制剂，例如Bortezomib、Carfilzomib和Ixazomib。除了这些类别之外，治疗方法选择还受到从一线到三线及以上治疗方案的考虑，以及从单一疗法到包括两种、三种和四种药物联合治疗在内的多种方案配置的影响。

最后，引言部分重点介绍了影响实际使用情况的实际变量，例如给药途径（静脉注射、口服、皮下注射等）、患者人口统计数据（60岁以上 vs 60岁以下）、性别差异的护理渠道以及分销渠道的差异（医院、线上药店、零售药店等）。透过阐明这些基本要素，本节将帮助管理人员和临床医生准确、结合情境解读后续章节。

深入研究从根本上改变多发性骨髓瘤治疗方法和商业化动态的治疗、交付和监管变化

多发性骨髓瘤的治疗模式正在经历一场变革，其驱动力在于机制多样化、优化的联合治疗以及以患者为中心的医疗服务模式。蛋白酶体抑制剂和免疫调节剂通常与单株抗体联用，以增强疗效的深度和持久性。同时，生技药品和免疫效应技术的日益成熟，正在重新调整研发重点，促使发起人寻求更早的适应症和合併用药策略，从而重新定义治疗标准。

科技变革也在重塑医疗保健服务。口服和皮下生技药品缩短了诊疗时间，并支持门诊病人管理。如今，治疗方法创新往往强调在一线治疗中采用三联或四联疗法（如果患者耐受），同时优先考虑序贯和联合治疗的灵活性，以应对二线及以上治疗的抗药性。这种转变伴随着监管和真实世界证据预期的不断变化，要求研发人员不仅要证明疗效，还要证明在生活品质、疾病进展预防和资源利用方面的相对效益。

因此，商业模式也在不断调整。製造商和医疗保健提供者必须根据不同治疗线的差异化临床特征调整产品定位，根据患者年龄组和性别定制通讯，并设计涵盖医院药房、零售店以及日益增长的线上渠道的分销策略。这将导致市场格局更加快速变化，细分化程度更高，而策略敏捷性和多学科证据产生能力将成为竞争优势。

对 2025 年关税政策变化如何重塑多发性骨髓瘤治疗的供应链、製造决策、价格谈判和获取管道的策略评估。

2025年美国新关税的实施将为全球医药供应链带来新的复杂性，影响采购、製造和成本管理。关税导致的成本上涨将影响原料药药物成分的采购、中间体成分以及某些进口生技药品，迫使製造商重新评估其供应商组合，并透过尽可能转移或本地化生产来减轻影响。这些策略调整将影响短期产业计画和长期产能资本投资。

同时，关税引发的波动将影响定价以及与付款人和综合配送网络的合约谈判。製药公司将面临压力，需要消化增加的成本、协商续约报销协议，并实施有针对性的患者支持策略以维持患者可及性。对于依赖复杂低温运输物流和专业配送的治疗方法，例如单株抗体的静脉注射，关税和不断上涨的物流成本将增加对综合供应链韧性的需求。

此外，关税促使人们重新评估不同治疗层级和给药偏好的商业策略。减轻临床负担的口服製剂可以抵御分销成本的波动，而医院的静脉注射疗法可能面临更严格的营运成本审查。对于决策者而言，关税措施的累积影响需要跨部门的应对，涵盖采购、监管规划、市场进入和价值沟通，以保障病患用药管道并维持医疗服务的连续性。

实证细分洞察揭示了药物类别、治疗线、方案架构、给药途径、人口统计和分布如何影响临床和商业性选择

这项研究的见解揭示了临床、人口统计和分布变数如何相互影响，从而影响治疗方法选择和商业性优先顺序。依药物类别分析，来Lenalidomide、Pomalidomide和Thalidomide等免疫调节剂仍是多种治疗方案的基石，通常与Bortezomib、Carfilzomib和Ixazomib等蛋白酶体抑制剂联合使用，构成骨干方案。Daratumumab、Elotuzumab和伊沙妥昔单抗等单株抗体越来越多地被用于联合治疗以增强疗效，而组蛋白去乙酰化酶抑制剂（如Panobinostat）在某些难治性治疗中也发挥作用。

治疗线从一线线到三线及以上细分，第一线治疗优先考虑耐受性和长期疾病控制，而后期治疗则强调挽救疗效和治疗顺序灵活性。单一疗法和联合治疗治疗方法之间的区别至关重要。联合治疗，无论是两种、三种或四种药物，都能提高缓解率，但也会增加毒性管理、支持性治疗和报销考量。依给药途径细分可以明确以病人为中心的权衡。静脉注射和皮下生技药品需要临床资源，而口服药物支持门诊管理，并可能提高依从性。

患者年龄组（60岁以上与60岁以下）和性别的差异会影响耐受性评估、合併症管理和移植合格，进一步优化治疗决策。最后，分销管道（医院、线上和零售药局）的细分影响着药物的可及性和病患体验，每个管道都有不同的物流、报销和病患支援要求。整合这些细分市场，可以製定量身定制的临床开发和商业策略，使产品特性与现实世界的治疗管道保持一致。

区域重点关注美洲、欧洲、中东和非洲地区以及亚太地区的治疗模式、监管流程、报销环境和人口结构差异

区域动态持续对多发性骨髓瘤治疗策略产生决定性影响，美洲、中东和非洲以及亚太地区各自展现出不同的临床实践、报销框架和患者人口统计。在美洲，重点是快速引入新型药物和组合方案，这得益于先进的临床实验室网络和鼓励明确价值差异化并根据实际疗效进行奖励的支付方环境。在该地区，关于药物可及性的讨论通常围绕着展示总体生存获益、改善无恶化生存期以及健康经济价值提案。

欧洲、中东和非洲地区医疗保健资金筹措模式和监管要求各异，因此需要製定针对特定地区的实证规划和定价策略。集中式监管管道与国家级报销决策并存，因此制定本地卫生技术评估文件和真实世界证据对于确保医疗资源的可及性至关重要。在该地区的许多国家，治疗提供模式强调医院管理，这影响了人们对皮下注射剂型和通讯协定的偏好，从而简化了输液中心的诊疗流程。

亚太市场受人口趋势和医疗现代化倡议的驱动，包括加速临床研究以及对口腔和门诊病人友善治疗的需求不断增长。供应链和关税政策在亚太部分地区也发挥关键作用，迫使製造商考虑区域製造伙伴关係和独特的分销模式。在整个地区，人口结构的变化，例如年龄分布和性别相关流行病学，将进一步影响产品定位和上市管道。

对竞争定位进行简明的策略回顾，其中现有特许经营权、新进业者和合作策略定义了临床差异化和商业性优势

多发性骨髓瘤领域的竞争动态将由既有的肿瘤学领导企业，也由敏捷的专业生物技术公司共同决定，这些公司将透过创新机制、联合用药策略和实证项目推动治疗差异化发展。以蛋白酶体抑制剂和免疫调节剂为中心的现有产品系列将继续在临床管道中发挥核心作用，而单株抗体业务则已扩展其适应症和服务模式，以支持临床和皮下给药。

新参与企业正透过双特异性抗体、细胞疗法和下一代标靶药物加速创新，迫使大型机构投资于联合测试和生命週期管理策略。策略活动包括透过领先测试扩大适应症，改进製剂以增强门诊病人给药，以及开发伴随诊断和生物标记策略以优化患者选择。随着企业寻求互补资产以建立稳健的治疗方案并扩大地域覆盖范围，伙伴关係和许可安排变得十分常见。

从商业性角度来看，企业正透过患者援助解决方案、数位化依从性计划以及将临床结果与成本和生活品质指标相结合的综合价值檔案来实现差异化。临床证据、生产规模和付款人参与度的相互作用将决定竞争定位，而成功的企业将是那些将科学差异化与卓越营运以及对医疗保健系统和患者可证明的价值相结合的企业。

为商业性和临床领导者提供可操作的协作策略步骤，以确保多发性骨髓瘤的可近性、优化治疗方案并增强供应弹性

致力于在多发性骨髓瘤领域奠定坚实基础的产业领导者应采取协调一致、切实可行的干预措施，以解决临床鑑别诊断、药物可近性和营运韧性等问题。这包括头对头试验和反映常规给药途径和患者群体的实用观察性研究。其次，他们应制定优化方案互换性的投资组合策略，使其能够将自身资产有效配置于双联、三联和四联治疗框架，同时兼顾耐受性和支持性治疗需求。

同时，投资于能够反映不断变化的医疗环境的分销和患者援助模式。尽可能加强门诊和家庭管理能力，并与医院药房相关人员和线上零售管道协同努力。多元化供应链和本地生产应急计划，以降低关税波动和物流中断带来的风险。从商业性角度来看，透过将临床终点与经济效益挂钩，完善与付款人的价值沟通，并制定有针对性的患者援助计划，以维持口服和注射药物的依从性。

最后，研发、市场准入和商业团队将跨职能合作，加速适应症扩大策略，并确保证据产生符合报销要求。透过实施这些协调一致的行动，产业领导者能够在快速发展的多发性骨髓瘤领域改善药物可及性、维持药物使用量并维持长期治疗相关性。

一种透明的多方法研究途径，结合主要专家访谈、系统文献综合和交叉检验的分析技术，以产生可靠的研究结果

本报告的调查方法严格整合了已发表的科学文献、监管备案文件、临床试验註册中心以及与临床医生、付款方和商业行业领袖的相关人员访谈。主要研究部分包括与多个执业机构的关键意见领袖和主治医生进行结构化访谈，以检验临床应用模式，并了解现实世界中的耐受性和用药偏好。次要研究部分包括对同行评审研究、监管文件和指南的系统性综述，以确定治疗机制、适应症和安全性。

采用交叉验证技术确保实验室结果与实际使用情况的一致性，并采用资料三角测量法协调不同资讯来源的发现。透过提取目标资料集并进行专家验证，实现了细分领域的覆盖，包括药物类别（组蛋白去乙酰化酶抑制剂、免疫调节剂、单株抗体、蛋白酶体抑制剂）、治疗线差异、方案结构、给药途径、患者年龄和性别组以及分销管道。区域分析资料来自监管文件以及对美洲、中东和检验以及亚太地区当地市场专家的访谈。

分析方法包括对访谈资料进行定性主题编码、不同治疗层级的效益风险比较评估，以及基于情境的影响模型，以评估关税效应和供应链调整等策略影响。调查方法的来源和限制保持透明，以提高可重复性并指导研究结果的适当解读。

整合临床创新、营运现实和政策动态的结论性综合报告，指导多发性骨髓瘤的策略决策

本执行摘要强调，多发性骨髓瘤是一个快速发展的治疗领域，临床创新、变革性交付模式和政策转变正在交织在一起，重新定义患者照护和商业策略。先进生技药品、优化组合方案和病患偏好给药途径的融合，需要采取整体方法进行证据产生、供应链设计和上市规划。将临床差异化与现实运作能力相结合的相关人员将最有能力将科学进步转化为持久的患者效益。

此外，诸如关税变化和区域监管差异等外部因素需要采取积极主动的跨职能应对措施，以维持药物的可及性和可负担性。整合细分洞察——从药物类别和治疗线到方案配置、给药途径、年龄/性别和分销管道——能够实现更精准的产品定位和量身定制的上市策略。最终，能否展示有意义的临床效益、管理物流复杂性以及向付款人和提供者传达价值，将决定哪些治疗方法能够获得持久的采用，哪些疗法面临可及性治疗方法。

因此，决策者应采取协作方式，在积极的证据生成和现实的商业化计划之间取得平衡，以确保治疗方法创新能够显着改善患者的治疗效果并为医疗保健系统带来价值。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • BCMA标靶CAR-T细胞疗法在復发/难治性多发性骨髓瘤患者的临床应用日益增多
  • 扩大口服蛋白酶体抑制剂联合治疗改善多发性骨髓瘤的第一线治疗效果
  • 下一代 cereblon E3 连接酶调变器的出现提高了多发性骨髓瘤的缓解率
  • 实施个人化微量残存疾病监测以指导多发性骨髓瘤治疗调整
  • 开发 BCMA 以外的多种骨髓瘤表面抗原的双特异性抗体平台
  • 扩大抗体-药物偶联物产品线，开发新型有效载荷，用于靶向多发性骨髓瘤治疗
  • 利用真实世界证据支持多发性骨髓瘤治疗药物的监管核准和市场进入
  • 整合先进的影像和液态生物检体生物标记物，用于多发性骨髓瘤復发的早期检测

第六章 2025年美国关税的累积影响

第七章 人工智慧的累积影响，2025年

8. 多发性骨髓瘤药物市场（依药物类别）

  • 组蛋白去乙酰化酶抑制剂
    • Panobinostat
  • 免疫调节药物
    • Lenalidomide
    • Pomalidomide
    • Thalidomide
  • 单株抗体
    • Daratumumab
    • Elotuzumab
    • 伊沙妥昔单抗
  • 蛋白酶体抑制剂
    • Bortezomib
    • Carfilzomib
    • Ixazomib

9. 多发性骨髓瘤药物市场（依治疗线）

  • 一线
  • 第二行
  • 三线以上

第 10 章：多发性骨髓瘤药物市场（依治疗方法）

  • 联合治疗
    • 双联疗法
    • 四联疗法
    • 三联疗法
  • 单一疗法

第 11 章：多发性骨髓瘤药物市场（依给药途径）

  • 静脉
  • 口服
  • 皮下

第 12 章：多发性骨髓瘤药物市场（依病患年龄）

  • 60岁或以上
  • 60岁以下

13. 多发性骨髓瘤药物市场（依性别）

  • 女士
  • 男性

14. 多发性骨髓瘤药物市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局

15. 多发性骨髓瘤药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 16 章：多发性骨髓瘤药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

17. 多发性骨髓瘤药物市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Bristol-Myers Squibb Company
    • Janssen BIoTech, Inc.
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Novartis International AG
    • AbbVie Inc.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Karyopharm Therapeutics Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-036C5CF3A894

The Multiple Myeloma Drug Market is projected to grow by USD 46.32 billion at a CAGR of 8.27% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 24.51 billion
Estimated Year [2025] USD 26.52 billion
Forecast Year [2032] USD 46.32 billion
CAGR (%) 8.27%

A comprehensive orienting overview that defines therapeutic classes, clinical decision nodes, and care delivery variables shaping multiple myeloma management

Multiple myeloma has evolved from a terminal hematologic malignancy to a complex, chronically managed disease area characterized by rapid therapeutic innovation and nuanced patient pathways. The landscape now interweaves targeted small molecules, immune-modulating compounds, biologics, and precision-directed platforms, each altering clinical practice patterns and payer conversations. Against this backdrop, stakeholders require a succinct, evidence-driven introduction that clarifies therapeutic categories, real-world administration pathways, and the commercial levers shaping adoption.

This executive introduction sets the stage by articulating the current therapeutic taxonomy and common clinical decision nodes. Drug classes of central relevance include histone deacetylase inhibitors exemplified by panobinostat, immunomodulatory agents such as lenalidomide, pomalidomide, and thalidomide, monoclonal antibodies including daratumumab, elotuzumab, and isatuximab, and proteasome inhibitors represented by bortezomib, carfilzomib, and ixazomib. Alongside these classes, treatment selection is influenced by line of therapy considerations spanning first line through third and beyond, and by regimen architecture that ranges from monotherapy to combination approaches including doublet, triplet, and quadruplet regimens.

Finally, the introduction underscores practical variables that shape real-world utilization: routes of administration including intravenous, oral, and subcutaneous delivery; patient demographic factors such as age cohorts sixty and above versus under sixty; gender-specific care pathways; and distribution channel distinctions across hospital, online, and retail pharmacy settings. By clarifying these foundational elements, this section equips executives and clinicians to interpret subsequent sections with precision and context.

An in-depth exploration of the therapeutic, delivery, and regulatory shifts fundamentally altering multiple myeloma treatment approaches and commercialization dynamics

Multiple myeloma treatment paradigms are undergoing transformative shifts driven by mechanistic diversification, combination optimization, and patient-centric delivery models. Over recent years, the field has moved beyond sequential monotherapy toward rationally designed combinations that leverage complementary mechanisms of action; proteasome inhibitors and immunomodulatory agents are commonly paired with monoclonal antibodies to enhance depth and durability of response. Concurrently, the maturation of biologics and immune effector technologies has reoriented R&D priorities, prompting sponsors to pursue earlier-line indications and combination strategies that redefine standard-of-care benchmarks.

Technological changes are also reshaping care delivery. Oral formulations and subcutaneous biologic options reduce clinic time and support outpatient management, which in turn influences payer negotiations and patient adherence dynamics. Treatment regimen innovation now frequently emphasizes triplet and quadruplet approaches in frontline settings where tolerability permits, while second-line and later settings prioritize sequencing and combination flexibility to manage resistance. These shifts are accompanied by evolving regulatory pathways and real-world evidence expectations, requiring developers to demonstrate not only efficacy but also comparative benefits in quality of life, progression control, and resource utilization.

As a result, commercial models are adapting: manufacturers and providers must align product positioning with differentiated clinical profiles across lines of therapy, tailor messaging for distinct patient age cohorts and genders, and design distribution strategies that incorporate hospital pharmacies, retail outlets, and increasingly important online channels. The net effect is a faster-moving, more fragmented landscape where strategic agility and multidisciplinary evidence generation confer competitive advantage.

A strategic assessment of how tariff policy shifts in 2025 are reshaping supply chains, manufacturing decisions, pricing negotiations, and access pathways in multiple myeloma care

The implementation of new United States tariff measures in 2025 has introduced an additional layer of complexity to global pharmaceutical supply chains, with implications for sourcing, manufacturing, and cost management. Tariff-driven cost inflation affects active pharmaceutical ingredient procurement, intermediate components, and certain imported biologic materials, prompting manufacturers to reassess supplier portfolios and, where feasible, repatriate or regionalize production to mitigate exposure. These strategic adjustments shape both short-term operational planning and longer-term capital investments in manufacturing capacity.

In parallel, tariff-induced changes influence pricing and contracting discussions with payers and integrated delivery networks. Pharmaceutical companies face pressure to absorb incremental costs, negotiate updated reimbursement terms, or implement targeted patient assistance strategies to preserve access. For therapies that rely on complex cold-chain logistics and specialized distribution-such as monoclonal antibodies administered intravenously or subcutaneously-the combination of tariffs and logistics cost increases intensifies the need for integrated supply chain resilience.

Moreover, tariffs catalyze a reevaluation of commercial strategy across therapeutic classes and route-of-administration preferences. Oral agents that reduce clinic burden can offer resilience against distribution cost volatility, while hospital-centric intravenous therapies may face more pronounced operational cost scrutiny. For decision-makers, the cumulative impact of tariff policy requires a cross-functional response that spans procurement, regulatory planning, market access, and value communication to sustain patient access and preserve therapeutic continuity.

Empirical segmentation insights revealing how drug class, therapy line, regimen architecture, administration route, demographics, and distribution converge to shape clinical and commercial choices

Segmentation-driven insight reveals how clinical, demographic, and distribution variables intersect to influence therapeutic selection and commercial priorities. When analyzing drug classes, immunomodulatory agents such as lenalidomide, pomalidomide, and thalidomide remain foundational across many lines of therapy and are frequently paired with proteasome inhibitors like bortezomib, carfilzomib, and ixazomib to create backbone regimens. Monoclonal antibodies, including daratumumab, elotuzumab, and isatuximab, are increasingly used in combination strategies to deepen responses, while histone deacetylase inhibitors exemplified by panobinostat occupy a role in selected refractory settings.

Line of therapy segmentation-spanning first line through third and beyond-drives regimen architecture, with frontline treatments prioritizing tolerability and long-term disease control, and later lines emphasizing salvage efficacy and sequencing flexibility. Treatment regimen distinctions between monotherapy and combination therapy are critical: combination approaches, whether doublet, triplet, or quadruplet, are driving improved response rates but also elevate considerations around toxicity management, supportive care, and reimbursement. Route of administration segmentation underscores patient-centric trade-offs; intravenous and subcutaneous biologics demand clinic resources, whereas oral agents support outpatient management and potentially higher adherence.

Patient age cohorts-sixty and above versus under sixty-and gender differences further refine therapeutic decisions, influencing tolerability assessments, comorbidity management, and transplant eligibility considerations. Finally, distribution channel segmentation across hospital, online, and retail pharmacies shapes access and patient experience, with each channel imposing distinct logistical, reimbursement, and patient support requirements. Integrating these segmentation lenses enables tailored clinical development and commercial strategies that align product attributes with real-world care pathways.

A regionally focused analysis of how treatment patterns, regulatory processes, reimbursement environments, and demographic trends vary across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to exert a decisive influence on multiple myeloma strategy, with the Americas, Europe Middle East & Africa, and Asia-Pacific each presenting distinct clinical practices, reimbursement frameworks, and patient demographics. In the Americas, practice patterns emphasize rapid adoption of novel agents and combination regimens, buoyed by advanced clinical trial networks and a payer environment that increasingly rewards clear value differentiation and real-world outcomes. Access conversations in this region are often centered on demonstrating overall survival benefit, progression-free survival improvements, and health economic value propositions.

In Europe, the Middle East, and Africa, heterogeneity in healthcare funding models and regulatory requirements necessitates region-specific evidence plans and pricing strategies. Centralized regulatory pathways coexist with country-level reimbursement decisions, making local health technology assessment dossiers and real-world evidence generation essential to secure access. In many countries across this region, treatment delivery models emphasize hospital-based administration, which influences preferences for subcutaneous formulations and protocols that streamline infusion center throughput.

Asia-Pacific markets demonstrate accelerating clinical research activity and rising demand for oral and outpatient-friendly therapeutics driven by demographic trends and healthcare modernization initiatives. Supply chain considerations and tariff policies also play a heightened role in some Asia-Pacific jurisdictions, prompting manufacturers to consider regional manufacturing partnerships and tailored distribution models. Across all regions, demographic variations such as age distribution and gender-related epidemiology further inform product positioning and market access pathways.

A concise strategic review of competitive positioning where incumbent franchises, novel entrants, and partnership strategies define clinical differentiation and commercial advantage

Competitive dynamics in multiple myeloma are defined by both established oncology leaders and agile specialty biotechs that drive therapeutic differentiation through novel mechanisms, combination strategies, and evidence-generation programs. Incumbent product portfolios anchored by proteasome inhibitors and immunomodulatory agents continue to play a central role in clinical pathways, while monoclonal antibody franchises have expanded indications and service models to support clinic-based and subcutaneous administration.

Emerging entrants are accelerating innovation through bispecific antibodies, cellular therapies, and next-generation targeted agents, compelling larger organizations to invest in combination trials and lifecycle management tactics. Strategic activity includes label expansion through earlier-line studies, formulation improvements that enhance outpatient delivery, and the development of companion diagnostics or biomarker strategies that refine patient selection. Partnerships and licensing arrangements are prevalent as companies seek complementary assets to build robust regimen offerings and to broaden geographic reach.

From a commercial perspective, companies are differentiating through patient support solutions, digital adherence programs, and integrated value dossiers that align clinical outcomes with cost and quality-of-life metrics. The interplay between clinical evidence, manufacturing scale, and payer engagement determines competitive positioning, and successful players will be those that align scientific differentiation with operational excellence and demonstrable value to health systems and patients.

Actionable and coordinated strategic moves for commercial and clinical leaders to secure access, optimize regimens, and strengthen supply resilience in multiple myeloma

Industry leaders seeking to strengthen their foothold in multiple myeloma should pursue a set of coordinated, actionable interventions that address clinical differentiation, access, and operational resilience. First, prioritize the generation of comparative and real-world evidence that demonstrates clinical benefit beyond existing standards of care across relevant lines of therapy; this includes head-to-head studies and pragmatic observational research that reflect routine administration routes and patient demographics. Second, design portfolio strategies that optimize regimen compatibility, enabling your assets to be convincingly positioned in doublet, triplet, or quadruplet frameworks while managing tolerability and supportive care needs.

Simultaneously, invest in distribution and patient support models that reflect shifting care settings: enhance capabilities for outpatient and home-based administration where feasible, and tailor engagement for hospital pharmacy stakeholders and online retail channels. Supply chain diversification and regional manufacturing contingency planning will mitigate exposure to tariff volatility and logistics disruption. From a commercial standpoint, refine value communication to payers by linking clinical endpoints to economic outcomes, and develop targeted patient assistance programs that maintain adherence across oral and injectable modalities.

Finally, embed cross-functional collaboration among R&D, market access, and commercial teams to accelerate label expansion strategies and to ensure evidence generation aligns with reimbursement requirements. By executing these linked actions, industry leaders can enhance access, sustain uptake, and preserve long-term therapeutic relevance in a rapidly evolving multiple myeloma landscape.

A transparent and multi-method research approach combining primary expert interviews, systematic literature synthesis, and cross-validated analytical techniques to ensure robust insights

The research methodology for this report combines a rigorous synthesis of public scientific literature, regulatory filings, clinical trial registries, and stakeholder interviews with clinicians, payers, and commercial leaders. Primary research components include structured interviews with key opinion leaders and treating physicians across multiple practice settings to validate clinical adoption patterns and to capture real-world tolerability and administration preferences. Secondary research involves systematic review of peer-reviewed studies, regulatory documentation, and guideline statements to map therapeutic mechanisms, label indications, and safety profiles.

Data triangulation was employed to reconcile insights from disparate sources, using cross-validation techniques to ensure consistency between clinical trial outcomes and observed real-world usage. Coverage of segmentation lenses-drug class including histone deacetylase inhibitors, immunomodulatory agents, monoclonal antibodies, and proteasome inhibitors; line of therapy distinctions; regimen architecture; route of administration; patient age and gender cohorts; and distribution channels-was achieved through targeted dataset extraction and expert validation. Regional analyses were informed by jurisdictional regulatory materials and interviews with local market experts in the Americas, Europe Middle East & Africa, and Asia-Pacific.

Analytical methods included qualitative thematic coding of interview data, comparative benefit-risk assessments across therapeutic classes, and scenario-based impact modeling to evaluate strategic implications such as tariff effects and supply chain adaptations. Throughout, transparency in source attribution and methodological limitations was maintained to support reproducibility and to guide appropriate interpretation of findings.

A concluding synthesis that integrates clinical innovation, operational realities, and policy dynamics to guide strategic decision-making in multiple myeloma

This executive synthesis underscores that multiple myeloma is a rapidly evolving therapeutic arena where clinical innovation, delivery model transformation, and policy shifts intersect to redefine patient care and commercial strategy. The convergence of advanced biologics, optimized combination regimens, and patient-preferred administration routes necessitates a holistic approach to evidence generation, supply chain design, and market access planning. Stakeholders who align clinical differentiation with pragmatic operational capabilities will be best positioned to translate scientific advances into sustained patient impact.

Moreover, external forces such as tariff changes and regional regulatory heterogeneity require proactive, cross-functional responses to preserve access and affordability. Integrating segmentation insights-from drug class and line of therapy through regimen composition, administration route, age and gender demographics, and distribution channels-enables more precise product positioning and tailored launch strategies. Ultimately, the capacity to demonstrate meaningful clinical benefit, manage logistical complexity, and communicate value to payers and providers will determine which therapies achieve durable uptake and which face access constraints.

Decision-makers should therefore take a coordinated approach that balances aggressive evidence generation with pragmatic commercialization planning, ensuring that therapeutic innovation translates into measurable improvements in patient outcomes and health system value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing clinical adoption of BCMA-directed CAR T-cell therapies in relapsed refractory multiple myeloma patients
  • 5.2. Expansion of oral proteasome inhibitor combination regimens improving frontline multiple myeloma treatment outcomes
  • 5.3. Emergence of next-generation cereblon E3 ligase modulators enhancing response rates in multiple myeloma
  • 5.4. Implementation of personalized minimal residual disease monitoring to guide therapy adjustments in multiple myeloma
  • 5.5. Development of bispecific antibody platforms targeting multiple myeloma surface antigens beyond BCMA
  • 5.6. Growing pipeline of antibody-drug conjugates combining novel payloads for targeted multiple myeloma therapy
  • 5.7. Use of real-world evidence to support regulatory approvals and market access for multiple myeloma therapies
  • 5.8. Integration of advanced imaging and liquid biopsy biomarkers for early detection of multiple myeloma relapse

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiple Myeloma Drug Market, by Drug Class

  • 8.1. Histone Deacetylase Inhibitors
    • 8.1.1. Panobinostat
  • 8.2. Immunomodulatory Agents
    • 8.2.1. Lenalidomide
    • 8.2.2. Pomalidomide
    • 8.2.3. Thalidomide
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Daratumumab
    • 8.3.2. Elotuzumab
    • 8.3.3. Isatuximab
  • 8.4. Proteasome Inhibitors
    • 8.4.1. Bortezomib
    • 8.4.2. Carfilzomib
    • 8.4.3. Ixazomib

9. Multiple Myeloma Drug Market, by Line Of Therapy

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third And Beyond

10. Multiple Myeloma Drug Market, by Treatment Regimen

  • 10.1. Combination Therapy
    • 10.1.1. Doublet Regimen
    • 10.1.2. Quadruplet Regimen
    • 10.1.3. Triplet Regimen
  • 10.2. Monotherapy

11. Multiple Myeloma Drug Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. Multiple Myeloma Drug Market, by Patient Age

  • 12.1. Sixty And Above
  • 12.2. Under Sixty

13. Multiple Myeloma Drug Market, by Gender

  • 13.1. Female
  • 13.2. Male

14. Multiple Myeloma Drug Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Multiple Myeloma Drug Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Multiple Myeloma Drug Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Multiple Myeloma Drug Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Bristol-Myers Squibb Company
    • 18.3.2. Janssen Biotech, Inc.
    • 18.3.3. Takeda Pharmaceutical Company Limited
    • 18.3.4. Amgen Inc.
    • 18.3.5. Novartis International AG
    • 18.3.6. AbbVie Inc.
    • 18.3.7. Sanofi S.A.
    • 18.3.8. GlaxoSmithKline plc
    • 18.3.9. Karyopharm Therapeutics Inc.
    • 18.3.10. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS